# A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

> **NCT00165451** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 20 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Thalidomide
- **DRUG:** Celecoxib
- **DRUG:** Etoposide
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00165451
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2011-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165451, "A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00165451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*